Eli Lilly (LLY)

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.8% in the afternoon session after JPMorgan's Chris Schott raised his pri...

Good medical care will always be in high demand, which makes some healthcare stocks strong long-term picks.

This key factor didn't exist when Buffett first gave the advice, but does that change its appeal?

Eli Lilly shares hit a new record high Tuesday after IPO stock Kailera posted lackluster test results for its obesity drug.

Shares of Eli Lilly have risen by over 40% since the company last reported earnings.

The stock has surged 160% over the past three years. Meanwhile, two key drugs could continue driving rampant growth.

Hims & Hers Health shares have surged 45% in 30 days on GLP-1 coverage shifts, but overbought technicals, a Hold rating, and rising short interest suggest a pullback may be near.

Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion.

The weight-loss market is crowded, but this company's lead drug candidate has several key advantages.

Lilly offers investors safety and growth.

Compare the portfolio concentration, risk profiles, and long-term growth of these two pharma ETFs.

One offers broad stability with lower costs and higher income, while the other chases biotech growth with 89.3% annual returns but steeper volatility.

This biotech might have a bright future, but it'll need to survive against the incumbents to do so.

Compare portfolio concentration, risk profiles, and long-term growth as these two pharma ETFs take different approaches to capturing sector opportunity.

Compare sector breadth, yield, and recent performance as these two healthcare ETFs take different approaches to growth and income.

Broad healthcare diversification or concentrated biotech growth? Compare cost, risk, and portfolio composition to find your fit.

Compare fees, diversification, and risk between these two leading healthcare ETFs.

The stock is known to soar on good news.

Johnson & Johnson doesn't need GLP-1 drugs to grow, and that's good news for long-term investors.

Investors are growing more optimistic over the company's pipeline and the initiation of a Phase 1 trial with a new drug.

Compare portfolio diversity, risk profiles, and income potential as you weigh these two leading healthcare ETFs.

Innovent and Eli Lilly sign a China commercialization deal for Verzenios, expanding patient access while Lilly retains manufacturing.

Eli Lilly (NYSE:LLY) has outperformed the market over the past 20 years by 7.2% on an annualized basis producing an average annual return of 16.46%. Currently, Eli Lilly has a market capitalization of $1.06 trillion.

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Phibro Animal Hea...

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Zoetis (NYSE:ZTS) and its pee...